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ABSTRACT 
Objective: The uncontrollable and excessive sweating is basically a disorder called Hyperhydrosis. Sweating is essential for thermal regulation but 
significantly impacts on the emotional and professional life of the people suffering from this. The aim of the present investigation was to observe the 
effectiveness of botulinum toxin type A in  patients with hyperhidrosis, the incidence of the disease, duration of the results and possible adverse effects. 
Methods: 27 patients with hyperhidrosis (axillary, palmar and axillary-palmar in combination) were treated with intradermal injection of 
botulinum toxin type A. Gender and racial compositions respectively was as follows; Male (n=17 or 63%): female (n=10 or 37%) and white (n=19 or 
70%): black (n=8 or 30%). In the case of axillary hyperhidrosis, local infiltrative anesthesia with subcutaneous injections (Lidocaine 1% with 
adrenaline) dosed with 20-50 ml for 30-240 min duration was used while locoregional anesthesia (Lidocaine 1% without adrenaline) dosed with 2-
5 ml was applied in the case of palmar hyperhidrosis. Diluted botulinum toxin was injected intradermally in an already anesthetized area. Each 
point was dosed with 2-4 U thus maximum total dose applied was 240 (60 x 4) for each anatomical region with hyperhidrosis (axillae and palm).  
Results: Axillary-palmar clinical condition was found to be the most common incidence of the disease followed by alone axillary and isolated 
palmar hyperhidrosis. More than 50% drop in the quantity of the sweating was observed at the completion of one month. Relapse in 12 % cases was 
reported. 64% patients were found be symptom-free for 9 mo. Only one patient showed side minor and easily manageable ecchymosis at a few 
points of intradermal injection and bilateral paresthesia hands and fingers.  
Conclusion: Botulinum toxin treatment is an effective, safe, and minimally invasive therapeutic treatment option, although it is costly. It helps 
enhances the quality of life of the patients and bring them out of stress, anxiety and emotional stress. 
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INTRODUCTION 
A disorder which leads to the uncontrollable and excessive sweating 
without any known triggering factor is termed as hyperhidrosis, 
which is manifested all across the gender at various ages [1]. 
Although sweating is essential for thermal regulation in the body 
especially during physical exercise, hyperhidrosis significantly 
impacts on the emotional and professional life of the people 
suffering from it, it is also observed that the symptoms stopped 
during sleep. Respondents with focal HH reported decreased 
participation in leisure activities and less time at work as a result of 
their perspiration. It is a genuinely serious condition that can lead to 
severe social impact such as isolation, social phobia, embarrassment, 
anxiety, physical discomfort, depression and other issues related 
with social life [2-4]. According to a national survey done in the USA 
revealed that hyperhidrosis is affecting 75 % of the population 
emotionally [5]. It is an equally common disorder as psoriasis [6], 
patients with diseases such as rheumatoid arthritis, multiple 
sclerosis and end-stage renal failure share almost the comparable 
quality of life with the patients suffering from hyperhidrosis [7-9]. 
However, patients who are suffering from this, seldom consult a 
physician as most of them are unaware that it is a clinically 
manageable illness. It is categorized as generalized (involvement of 
the whole body) and focal (involvement of a limited body area). 
Primary hyperhidrosis is the quotidian clinical form of hyperhidrosis 
constituting focal, an idiopathic, chronic, bilateral, and symmetrical 
variation in sweating process. A sympathetic autonomous nervous 
system that controls the eccrine sweat glands which produce sweat 
in response to change in body temperature and so the hyperactivity 
of the autonomic nervous system, triggers glandular hypertrophy 
and hypersecretions of the sweat gland leading to primary 
hyperhidrosis [10, 11]. There has been some evidence of genetic 
abnormality with primary hyperhidrosis as in 30% to 50% cases 
family history of the disorder has been noticed [12, 13]. Autonomic 
neuronal dysfunction seems to be involved mainly in the areas sweat 
glands are a higher number such as the soles (plantar), palms 
(palmar) and axillae (axillary but less common on the scalp and 
facial region [14, 15]. Axillary hyperhidrosis is commonly bilateral 
pattern and may be triggered by mental stress, heat and is allied 
with complications such as contact dermatitis [16]. Various types of 
conservative treatment options for hyperhidrosis are there such as 
topical agents (aluminium salts), oral anticholinergic agents 
(methantheline, oxybutynin and) and adrenergic agonists 
(clonidine), iontophoresis, application of botulinum toxin as well as 
surgical treatment (Subdermal axillary liposuction, thoracic 
sympathectomy-video assisted, and retroperitoneoscopic lumbar 
sympathectomy-video-Assisted). The adverse effect of topical agents 
is skin irritation due to high salt concentration [17] and of oral 
agents is blurred vision, urinary hesitancy, marked tachycardia, 
dizziness and confusion while that of iontophoresis is dryness of 
mouth, dizziness, constipation, sedation and symptomatic drop in 
blood pressure [18]. The above-mentioned treatment modalities 
genuinely vary in the time duration of therapeutic effect, related 
adverse effects and treatment cost, and scientific evidence of their 
therapeutic efficacy. A neurotoxin (botulinum toxin) was considered 
as a deadly substance for several years. Clinical features of the 
botulism were in explained in 19th century [19] but in the 1970’s 
botulinum toxin was as significant research tool to investigate the 
spinal cord physiology. In 1980’s evidence of therapeutic potential of 
botulinum toxin (BT) had emerged and over last 3 decades it has 
been observed to be immensely beneficial for the successful 
treatment of many conditions such as movement disorders, pain 
management, ophthalmic disorder, pelvic floor and gastrointestinal 
disorders and various cosmetic disorders [20] Botulinum toxin is a 
neurotransmitter, acetylcholine blocker, so it blocks synaptic 
transmission resulting in chemical denervation of the glands and 
temporary cessation of hyperhidrosis. Treatment of primary 
hyperhidrosis with botulinum toxin A is an easy treatment. Prior to 
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the administration, the botulinum toxin A the targeted region is 
anesthetized with either topical, locoregional anesthesia or even 
sedation. However, it has some disadvantage a temporary 
therapeutic action (7 mo), costly the uneasiness allied with multiple 
point injections [21, 22]. Primary hyperhidrosis affects people all 
over the world including Kingdom of Saudi Arabia with almost 2.8% 
of US population but the limited scientific investigation regarding 
the therapeutic efficacy, duration of its effect, adverse effect and 
satisfaction of the patients with this treatment option in Saudi 
Arabia has been carried out and so, the availability of research data 
is scarce to nonexistent [23-30]. The present investigation was 
aimed to evaluate the effectiveness, safety and adverse effects of 
botulinum toxin A and satisfaction of the patients with this 
therapeutic option in the population of Riyadh region of KSA with 
axillary and palmar hyperhidrosis. 
Patients and method 
Recruitment of patients 
Patients suffering from primary hyperhidrosis were recruited 
from Riyadh region of the kingdom of Saudi Arabia following the 
ethical approval wide letter No. EA/CM/10/08/2014 Clinical 
history is taking and thorough examination of all the patients 
was carried out and well documented. Patients including all the 
genders (n=27) with primary axillary and palmar hyperhidrosis 
resistant to earlier treatment of topical agents were given 
conservative treatment after taking written consent from them 
using intradermal injections of botulinum toxin type-A. The age 
of all the patients ranged between 18 and 50 y with gender and 
racial compositions respectively was as follows; Male (n=17 or 
63%): female (n=10 or 37%) and white (n=19 or 70%): black 
(n=8 or 30%). The study was accomplished between May 2011 
and Jan 2016. All those patients exhibiting the amount of 
sweating higher or equal to 50 mg/minute measured by 
quantitative gravimetric analysis were included in the study. 
Exclusion criteria 
Exclusion criteria involved in the present study was based on 
underlying severe systemic diseases, thyroid diseases, diabetes 
mellitus, neuromuscular alteration. Patients with the historical 
background of botulinum toxin sensitivity, usage of calcium channel 
blocker, aminoglycoside category of antibiotics, muscle relaxant, 
acetylsalicylic acid, and with recent surgery, infectious and 
inflammatory conditions in the skin or at the place of botulinum 
toxin application were also excluded from the study [31]. Pregnant 
and breastfeeding women, patients on systemic medications and 
with those with secondary hyperhidrosis were excluded too. 
Determination of intensity of hyperhidrosis 
The intensity of the hyperhidrosis together with the most affected 
area was assessed using Minor’s test (starch-iodine test) which was 
carried out by application of 10% povidone iodine over the axillary 
and palmar cutaneous surface followed by the application of a very 
thin layer maize starch for 5-10 min.  
The dark violet color developed due to the reaction in the area of 
excessive sweating was evaluated to understand the intensity 
and affected location. Quantitative gravimetry was carried out 
before application, 15 d after, and every month over the period 
of one year. A filter paper was previously weighed on a very 
high-precision laboratory scale and the weight was recorded. 
The paper was then placed into the axillary cavity and on the 
cutaneous surface of palm for exactly 1 minute. The paper was 
taken back and weighed again to calculate the rate of sweat 
secretion per minute [37, 38]. 
Reconstitution and storage of Botulinum Toxin-A 
Due to the fragile nature of botulinum toxin, its reconstitution was 
handled carefully by introducing non-preserved normal saline (0.9% 
of sodium chloride as most preferred diluent) gently into the 
botulinum toxin-A vial in order to avoid foaming formation during 
reconstitution which could interfere with the results [32, 33]. The 
reconstituted botulinum toxin was stored in the refrigerator at 2-8 
°C used within 3-4 h.  
Dose-dependent dilution of botulinum toxin 
The content of each flask possesses 100 U of type A botulinum toxin, 
0.5 mg of human albumin and 0.9 mg of sodium chloride in a 
sterilized, vacuum-dried form without a preservative [34]. Each vial 
was diluted with 4 cc of normal saline (0.9%) solution to achieve the 
final concentration of toxin 25 U/cc.  
Administration of the diluted botulinum toxin (25 U/cc) 
Intradermal injection of type A botulinum toxin was performed 
under different anesthesia depending upon anatomical position of 
hyperhidrosis. In case of axillary hyperhidrosis local infiltrative 
anesthesia with subcutaneous injections (Lidocaine 1% with 
adrenaline) dosed with 20-50 ml for 30-240 min duration was used 
while locoregional (blocking of the median, radial, and ulnar nerves) 
anesthesia (Lidocaine 1% without adrenaline) dosed with 2-5 ml 
(habitual volume by each point of infiltration) was applied in case of 
palmar hyperhidrosis. Multiple-points marking (thirty-sixty points 
with a distance of 1-2 cm between them on each side of the axillary 
and palmar region) was carried out to ensure the equal distribution 
of the toxin so as to get an efficient result. Diluted botulinum toxin 
was injected intradermally in an already anesthetized area using 1 
ml syringe (4 mm 30 G needle) at an angle of 30 ° to the skin surface 
and a mean depth of 4 mm. Each point was dosed with 2-4 U thus 
total maximum dose applied was 240 (60 x 4) for each anatomical 
region with hyperhidrosis (axillae and palm). The entire procedure 
took 30-60 min with an average of 45 per session and the session 
was repeated every seven months [34].  
RESULTS  
Out of the total 27 only 25 patients successfully completed the one 
year of follow-up while 2(7.40%) patients (white female) failed to 
follow after third consultation owing to their personal reason. 2(8%) 
female and 5(20%) male patients were presenting isolated axillary 
hyperhidrosis while isolated palmar hyperhidrosis was observed in 
2(8%) female and 4(16%) male patients. Axillary-palmar 
hyperhidrosis was observed in the case of four (16%) female and 
eight (32%) male patients which was the most common clinical 
conditions (fig. 1). Evaluation of sweat production of both the 
axillary and palmar area was measured by gravimetric assessment. 
Monthly percentage change in the quantity of sweat production 
determined for all the patients to observe the therapeutic effects of 
the botulinum toxin. 50% or more than 50% drop at one month in 
the production of sweat measured by gravimetric assessment was 
set as a criterion for the treatment given to be successful. After 
completion of the first month, almost all the patients were found to 
have successful treatment for isolated axillary and palmar as well as 
axillary-palmar hyperhidrosis as the sweat rate (mg/min.) was 
found to be significantly reduced by 98.1%. (in case of axillary 
hyperhidrosis), 97.4 % (in the case of palmar hyperhidrosis) and by 
96.9% in case axillary-palmar hyperhidrosis. Evidence of sweat 
production in more than 50% (relapse) was found in only three 
patients (12%), 2 with axillary-palmar and 1 with axillary 
hyperhidrosis after three months of the commencement of the 
treatment who received small reinforcement botulinum toxin dose 
intradermally to treat the affected area. 11 patients had a family 
history of hyperhidrosis (4 axillary, 2 palmar and 5 axillary-palmar). 
Patients with longer prior-treatment duration of the disease (ranged 
2-7 y) experienced the shorter post-treatment period of anhidrosis. 
A significant difference between both hands and both sides of axillae 
was not observed in any case (dominant versus non-dominant). The 
time duration of the therapeutic benefits of the toxin was observed 
to be ranged from 3-12 mo with the maximum number of patients 
benefited with prolonged time duration of a decrease in symptoms 
depending upon follow-up assessment and patients close 
observation was found to be 9 mo which has been detailed in fig. 2. 
Questionnaire based evaluation of results and tolerability was 
carried out to analyze the satisfaction level of the patients and 
possible side effects respectively. 88% of the patients were found to 
be very satisfied with the results, even though the temporary nature 
of the treatment. Compensatory sweating in 3 patients was recorded 
in the minor quantity not enough to disturb the quality of life. The 
Vascular deficit of hands and any neurological deficit were not 
evidenced. Self-limiting ecchymosis at a few points of intradermal 
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injection and bilateral paresthesia hands and fingers were observed 
in 4 patients. Only one male patient had a complaint of ecchymosis at a 
few points of intradermal injection and bilateral paresthesia hands and 
fingers with allied neuropathic pain and decrease in muscular force (oral 
ibuprofen and physiotherapy consultation was advised to him)  
 
 








Keeping the risk associated, complications, limitations and adverse 
effects of different treatment options of hyperhidrosis, intradermal 
injection of type A botulinum toxin (conservative treatment) opted 
as therapeutic option in the present study as it has high satisfaction 
rate, minor complications and side effects [35, 36] while poor 
satisfaction rate, increased risks and permanent complications have 
been noticed with surgical options of treatment [37]. Use of 
botulinum toxin is preferable as synaptic transmission block is 
achieved to cause a drop in symptoms and perhaps it causes atrophy 
and involution of various eccrine sweat glands [38] 48% axillary-
palmar, 24% isolated palmar and 28 isolated axillary cases were 
recorded during the consultation for hyperhidrosis. However, 
Grunfeld et al. [39] reported a high incidence of isolated axillary 
hyperhidrosis (51%), followed by isolated palmar (24%). The time 
duration of the therapeutic benefits of the toxin was observed to be 
ranged from 3-12 mo with the maximum number of patients 
benefited with prolonged time duration of a decrease in symptoms 
was found to be 9 mo. Benefit for up to 9 mo observed in 64% 
patients, for 7 mo in 16%, for 3 mo in `12% while 4% patients 
reported for one complete year which confirmed the efficacy of the 
botulinum toxin type in decreasing the hyperhidrosis (axillary, 
palmar and axillary-palmar). Solomon and Hayman [40] reported a 
significant reduction in recalcitrant palmar and digital hyperhidrosis 
using botulinum toxin type A dosed with 165 U/hand with 
anhidrosis lasting for 4-9 mo while reduced quantity of sweating 
remained in all the patients for 12 mo. In one study Lowe et al. [41] 
reported the use of Botox® versus placebo for the treatment of 
palmar hyperhidrosis in 19 patients and concluded that patients 
experienced a significant improvement in palmar hyperhidrosis. 
Only one male patient had a complaint of ecchymosis at a few points 
of intradermal injection and bilateral paresthesia hands and fingers 
with allied neuropathic pain and decrease in muscular force which 
were possible related to a minor-trauma of nervous and vascular 
structures during the period of the anaesthetic block. Neuropathic 
pain was the part of reflex sympathetic dystrophy and causalgia 
(syndrome) caused by injury to the peripheral nerves during 
anesthetic drug infiltration. Baron and Zloty [42] reported a clinical 
case with complex regional pain syndrome during treatment of 
palmar hyperhidrosis; the syndrome diminished after clinical 
treatment and physiotherapy consultation [43]. 
Limitations of the study 
A variety of the studies has been done by the researcher targeting 
Hyperhidrosis: its diagnosis and treatment, botulinum toxin type A, 
as an effective treatment for hyperhidrosis. Still this disease is 
treated as a social stigma in the society so a lot to be done on this. On 
the other hand botulinum toxin type, A has some adverse effect, high 
cost and complicated method of application. So there is the need for 
further research and development to find out the novel agents to 
treat hyperhidrosis with low cost and easy route of application. The 
present investigation will prompt researchers as a platform for 
further research and development in this field. 
CONCLUSION  
Application intradermal injection of type A botulinum toxin is a good 
therapeutic option for the treatment of isolated axillary, palmar and 
axillary-palmar hyperhidrosis as it has higher effectiveness, with 
greater safety and minimum invasiveness. It imparts a greater 
degree of satisfaction to the patients and makes them able to do a 
successful commencement of professional and social activities. 
Though treatment cost is high, it is precise and easily implementable 
techniques with temporary and infrequent adverse effects and 
associated complications. It helps enhances the quality of life of the 
patients and bring them out of stress, anxiety and emotional stress.  
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